Minjuvi (Tafasitamab)

• Minjuvi (tafasitamab) is employed in the treatment of B‑cell malignancies, particularly diffuse large B‑cell lymphoma, a fast‑growing non‑Hodgkin lymphoma that can be resistant to prior therapies.
• Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL): Used in combination with lenalidomide to achieve disease control in adult patients.
• Combination with lenalidomide: Provides synergistic activity that improves response rates in relapsed/refractory DLBCL.
• Adult patients (≥18 years): Approved for individuals 18 years and older with relapsed or refractory DLBCL.

• Tafasitamab is a humanized IgG1 monoclonal antibody that binds with high affinity to the CD19 antigen expressed on B‑cell surfaces. This binding recruits immune effector cells, triggering antibody‑dependent cellular cytotoxicity (ADCC) and may also induce direct apoptosis of malignant B‑cells, thereby reducing tumor burden and limiting disease progression.

Common Side Effects

• Infusion‑related reactions: flushing, chills, or shortness of breath during or shortly after administration.
• Fatigue: generalized tiredness that may affect daily activities.
• Nausea: mild to moderate upset stomach, often transient.

Serious or Rare Side Effects

• Severe infections: increased susceptibility to bacterial, viral, or fungal infections.
• Cytopenias: significant reductions in white blood cells, platelets, or hemoglobin.
• Hepatic toxicity: elevated liver enzymes or liver dysfunction.
• Anaphylaxis: rare but potentially life‑threatening allergic reaction.
• Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances.

Before initiating therapy, clinicians should assess patient suitability and monitor for adverse events.

• Infusion reactions: monitor vital signs during and after infusion.
• Blood counts: perform regular complete blood count assessments.
• Liver function: evaluate hepatic enzymes periodically.
• Active infections: avoid use in patients with uncontrolled infections.
• Pregnancy and breastfeeding: safety not established; weigh risks and benefits.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tafasitamab may interact with other agents that affect immune function or hematologic parameters.

Major Interactions (Avoid)

• Concurrent monoclonal antibodies: increased risk of immunosuppression and overlapping toxicities.
• Live vaccines: contraindicated due to potential for uncontrolled infection.
• Strong CYP450 inducers (affecting lenalidomide): may alter lenalidomide exposure when used together.

Moderate Interactions (Monitor Closely)

• Lenalidomide: monitor for additive cytopenias and adjust dosing as needed.
• Anticoagulants: observe for enhanced bleeding risk.
• Other immunosuppressants: increased susceptibility to infections.